Ipsen Pharma, Novartis AG, Pfizer Inc. are Dominating the U.S. Acromegaly Drugs Market in 2019

U.S. Acromegaly Drugs Market is expected to grow with the CAGR of 6.4% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/us-acromegaly-drugs-market

U.S. acromegaly drugs market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.   

The major players dealing in the U.S. acromegaly drugs market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition, agreement, business expansion, award and recognition into the market. This helped companies to maximize the sales with enhanced product portfolio.

For instance,

  • In June 2020, Chiasma, Inc. announced the U.S. Food and Drug Administration (FDA) approval for Mycapssa (octreotide) capsules for long-term maintenance treatment in acromegaly. This approval will enhance the company position in the U.S. market as well as FDA approval will propel the company growth in the coming years.

Ipsen Pharma is the dominating player in the U.S. acromegaly drugs market. The other key players existing in the market includes Novartis AG, Mylan N.V., Pfizer Inc., Fresenius Kabi USA (A Subsidiary of Fresenius Kabi AG), Zydus Pharmaceuticals Inc. (a subsidiary of Zydus Cadila), Par Pharmaceuticals (A Subsidiary of Endo International plc), Hikma Pharmaceuticals PLC, Teva Pharmaceuticals USA, Inc. (A Subsidiary of Teva Pharmaceutical Industries Ltd.), Chiasma, Inc., Ingenus Pharmaceuticals, LLC, Recordati Rare Diseases (A Subsidiary of RECORDATI S.p.A.), Sun Pharmaceutical Industries Ltd. and Sagent Pharmaceuticals, Inc. (A Subsidiary of Nichi-Iko Pharmaceutical Co., Ltd.) among others.

U.S. Acromegaly Drugs MarketIpsen Pharma  

Ipsen Pharma is headquartered in Paris, France and was founded in 1929; the company has primary focus on oncology, neuroscience and rare diseases. Moreover company is concentrating on novel solutions for targeted debilitating diseases continuous to benefit patient as well as improve their lives through innovative medications in oncology. The company has business segments such as specialty care, consumer healthcare. In this specialty care is the market focussed segment. The company has wide product portfolio such as oncology, neuroscience, rare disease, consumer healthcare in which rare diseases is the market focused category.

For instance,

  • In April, 2019 Ipsen pharma completed acquisition of Clementia Pharmaceuticals. This acquisition will help to deliver new, impactful therapies for people affected by cancer and rare diseases. Resulting, it has anticipated to boom Ipsen pharmaceutical’s revenue growth.

The company has a wide presence across Europe, North America, Asia-Pacific, South America. The company also has various subsidiary companies such as Linnea SA (Switzerland), Ipsen Pharma SAS (France), Ipsen, Inc. (U.S.), IPSEN BIOSCIENCE INC. (U.S.), Syntaxin Ltd (U.K.) among others.     

Novartis AG

Novartis AG is headquartered in Basel, Switzerland and was founded in 1996. The company is solely focusing on the most promising frontiers of science, the most exciting innovations in medicine and the most important health needs. The company has business segments including innovative medicines, sandoz among which innovative medicines is the marker focused category. The company has wide product categories including sandostatin SC, rydapt, proleukin, piqray, pazeo, patanol, myfortic, tabrecta, tafinlar, tegretol, tobradex, travatan, trileptal, tyverb, ultibro breezhaler, signifor LAR among others among which signifor LAR, sandostatin SC are the market focussed category.

For instance,

  • In November, 2019 Novartis AG acquired The Medicines Company to acquire the US-based biopharmaceutical company. This acquisition has been estimated to raise the company presence in U.S. market. Consequently it will propel the revenue growth of the company.

The company has presence in Asia Pacific, Europe, and Middle East, America. The company has several owned subsidiaries involving IFM Therapeutics (U.S.), Takeda Pharmaceuticals (Tokyo), Sandoz Pharmaceuticals (Holzkirchen, Bavaria) and others.

Pfizer Inc.

Pfizer Inc. is headquartered in New York, United State and was founded in 1849. The company is exclusively concentrating on medicines that are used in hospitals to serving the customers and developing the relationships. Furthermore company is primarily focusing on R&D of oncology, vaccines, rare diseases, internal medicine and hospital segment. The company has various business segments such as biopharma, upjohn and consumer healthcare among which biopharma is the market focused segment.  The company is engaged in providing wide range of product categories such as somavert, celebrex, diflucan, lyrica, ibrance, norvasc, chantix, lipitor, eliquis and many others among which  Somavert is the market focused product category.  

For instance,

  • In June 2019, Pfizer Inc. announced acquisition with Array Biopharma Inc. This has helped to strengthen Pfizer Inc’s innovative biopharmaceutical business as well as to accelerate its growth trajectory particularly in the long term which has anticipated strengthening leadership in the global market.

The company is present in Europe, Middle East and Africa, Americas, Asia-Pacific. The company has several owned subsidiaries involving Pfizer Animal Health B.V. (the Netherlands), Pfizer Asia International B.V. (Netherlands), Pfizer Australia Superannuation Pty Ltd (Australia), Pfizer Dominicana, S.A. (Dominican Republic), and Pfizer Egypt S.A.E. (Egypt) among others.